Annual report pursuant to Section 13 and 15(d)

Collaboration and License Agreements and Supply Agreements - Summary of Recognized Revenue (Details)

v3.24.1
Collaboration and License Agreements and Supply Agreements - Summary of Recognized Revenue (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Total revenue $ 153,731 $ 67,772 $ 61,880
Vaxcyte Agreements      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Total revenue 101,302 3,828 3,041
Vaxcyte Agreements | Upfront Payment      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Total revenue 97,500    
Vaxcyte Agreements | Research and Development Services      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Total revenue 2,435 2,356 1,131
Vaxcyte Agreements | Materials Supply      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Total revenue 1,367 1,472 1,910
Collaboration and License Agreements and Supply Agreements      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Total revenue 153,731 67,772 61,880
Collaboration and License Agreements and Supply Agreements | Bristol-Myers Squibb Company ("BMS")      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Total revenue 5,590 9,752 11,483
Collaboration and License Agreements and Supply Agreements | Merck Sharp & Dohme Corporation ("Merck")      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Total revenue 5,869 11,600 42,780
Collaboration and License Agreements and Supply Agreements | Merck KGaA, Darmstadt, Germany (operating in the United States and Canada under the name ''EMD Serono'')      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Total revenue 8 2,695 4,576
Collaboration and License Agreements and Supply Agreements | Astellas Pharma Inc. ("Astellas")      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Total revenue 33,992 10,897  
Collaboration and License Agreements and Supply Agreements | Tasly Biopharmaceuticals Co., Ltd. ("Tasly")      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Total revenue 6,970 25,000  
Collaboration and License Agreements and Supply Agreements | Vaxcyte, Inc.      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Total revenue 101,302 3,828 3,041
Collaboration and License Agreements and Supply Agreements | BioNova Pharmaceuticals, Ltd. ("BioNova")      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Total revenue   4,000  
BMS Agreement and the 2018 BMS Master Services Agreement      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Revenues 5,590 9,752 11,483
BMS Agreement and the 2018 BMS Master Services Agreement | Research and Development Services      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Revenues 412 700 940
BMS Agreement and the 2018 BMS Master Services Agreement | Materials Supply      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Revenues 5,178 9,052 10,543
2020 Merck Master Services Agreement      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Total revenue 5,869 11,600 42,780
2020 Merck Master Services Agreement | Ongoing Performance Related to Unsatisfied Performance Obligations      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Total revenue   862 35,098
2020 Merck Master Services Agreement | Contingent Payment      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Total revenue   10,000  
2020 Merck Master Services Agreement | Research and Development Services      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Total revenue 245 577 2,666
2020 Merck Master Services Agreement | Financing Component on Unearned Revenue      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Total revenue     610
2020 Merck Master Services Agreement | Materials Supply      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Total revenue 5,624 161 4,406
2019 EMD Serono Supply Agreement      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Total revenue 8 2,695 4,576
2019 EMD Serono Supply Agreement | Contingent Payment      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Total revenue     2,000
2019 EMD Serono Supply Agreement | Research and Development Services      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Total revenue 6 510 851
2019 EMD Serono Supply Agreement | Materials Supply      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Total revenue 2 2,185 $ 1,725
Astellas License and Collaboration Agreement      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Total revenue 33,992 10,897  
Astellas License and Collaboration Agreement | Ongoing Performance Related to Unsatisfied Performance Obligations      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Total revenue 17,015 3,940  
Astellas License and Collaboration Agreement | Research and Development Services      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Total revenue 6,584 1,878  
Astellas License and Collaboration Agreement | Financing Component on Unearned Revenue      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Total revenue 9,836 5,079  
Astellas License and Collaboration Agreement | Materials Supply      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Total revenue 557    
Tasly License Agreement      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Total revenue 6,970 25,000  
Tasly License Agreement | Upfront Payment      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Total revenue   $ 25,000  
Tasly License Agreement | Contingent Payment      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Total revenue 5,000    
Tasly License Agreement | Research and Development Services      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Total revenue 92    
Tasly License Agreement | Materials Supply      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Total revenue $ 1,878